#1 Clinical Trials Search in Europe

Etoposide Phosphate

Etoposide phosphate is an anticancer drug being studied in various clinical trials for the treatment of different types of cancer. This article examines how etoposide phosphate is being used and evaluated in combination with other therapies to potentially improve outcomes for patients with conditions like lymphoma, leukemia, and other malignancies. The trials aim to determine optimal dosing, efficacy, and safety of etoposide phosphate-containing regimens.

Table of Contents

What is Etoposide Phosphate?

Etoposide Phosphate is a chemotherapy drug used to treat various types of cancer. It is a water-soluble form of etoposide, which makes it easier to prepare and administer[1]. This medication is also known by other names, including:

  • Etopophos®
  • VP-16
  • Vepesid®

Etoposide Phosphate is a prodrug, which means it is converted into its active form (etoposide) once it enters the body. This conversion happens quickly and completely after intravenous administration[2].

What Conditions Does Etoposide Phosphate Treat?

Etoposide Phosphate is used to treat several types of cancer, including:

  • Small Cell Lung Cancer (SCLC): This is an aggressive form of lung cancer that often responds well to chemotherapy[3].
  • Non-Hodgkin’s Lymphoma: A type of cancer that affects the lymphatic system[4].
  • Glioblastoma Multiforme: An aggressive brain cancer[2].
  • Relapsed or Refractory Hematologic Malignancies: These are blood cancers that have either come back after treatment or did not respond to initial treatment[5].

How Does Etoposide Phosphate Work?

Etoposide Phosphate works by interfering with the DNA in cancer cells. Specifically, it inhibits an enzyme called topoisomerase II, which is essential for DNA replication. By blocking this enzyme, Etoposide Phosphate prevents cancer cells from dividing and growing[3].

This mechanism of action makes Etoposide Phosphate effective against rapidly dividing cells, such as cancer cells. However, it can also affect normal cells in the body that divide quickly, which is why side effects can occur.

How is Etoposide Phosphate Administered?

Etoposide Phosphate is typically given as an intravenous (IV) infusion. The dosage and schedule can vary depending on the specific condition being treated and other factors. Some common administration methods include:

  • Daily infusions for 3-5 days, repeated every 3-4 weeks[4].
  • As part of a combination therapy regimen with other chemotherapy drugs[5].
  • In some cases, it may be given as a continuous infusion over a longer period[2].

One advantage of Etoposide Phosphate over regular etoposide is that it can be prepared in higher concentrations, allowing for shorter infusion times or smaller infusion volumes[2].

Etoposide Phosphate in Combination Therapies

Etoposide Phosphate is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

  • With carboplatin for treating small cell lung cancer[3].
  • With cisplatin for treating recurrent ependymomas (a type of brain tumor)[1].
  • With bendamustine and clofarabine for treating relapsed or refractory hematologic malignancies in younger patients[5].

Potential Side Effects

Like all chemotherapy drugs, Etoposide Phosphate can cause side effects. Some potential side effects include:

  • Myelosuppression: This is a decrease in blood cell production, which can lead to increased risk of infection, anemia, and bleeding[5].
  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Decreased appetite

Your healthcare team will monitor you closely for these and other side effects during treatment. They may adjust your dose or provide supportive care to manage side effects if they occur.

Ongoing Research and Clinical Trials

Researchers continue to study Etoposide Phosphate to find new ways to use it effectively and safely. Some ongoing areas of research include:

  • Using Etoposide Phosphate in combination with focused ultrasound to treat diffuse midline glioma, a type of brain tumor in children[6].
  • Investigating the relationship between genetic variations (called single nucleotide polymorphisms or SNPs) and how patients respond to Etoposide, including its effectiveness and side effects[3].
  • Exploring new combination therapies, such as combining Etoposide Phosphate with immunotherapy drugs like Atezolizumab for treating large cell neuroendocrine carcinoma of the lung[7].

These ongoing studies aim to improve treatment outcomes and reduce side effects for patients receiving Etoposide Phosphate.

Aspect Details
Cancer Types Studied Non-Hodgkin’s lymphoma, Hodgkin lymphoma, acute leukemias, diffuse midline gliomas, NUT carcinoma
Administration Method Intravenous (IV) infusion, typically over multiple days
Combination Therapies Carboplatin, cisplatin, clofarabine, mitoxantrone, bendamustine, molibresib
Key Objectives Determine safety, optimal dosing, efficacy, side effects, drug interactions
Unique Approaches Focused ultrasound to open blood-brain barrier for improved drug delivery
Outcome Measures Maximum tolerated dose, dose-limiting toxicities, response rates, progression-free survival, overall survival

FAQ

  • What types of cancer is etoposide phosphate being studied for? Etoposide phosphate is being studied for various cancers including non-Hodgkin's lymphoma, Hodgkin lymphoma, acute leukemias, diffuse midline gliomas, and NUT carcinoma.
  • How is etoposide phosphate typically administered in these trials? Etoposide phosphate is typically administered intravenously (IV) over multiple days as part of chemotherapy regimens. The exact dosing and schedule varies between trials.
  • What are some drugs etoposide phosphate is being combined with? Etoposide phosphate is being studied in combination with drugs like carboplatin, cisplatin, clofarabine, mitoxantrone, bendamustine, and molibresib in various trials.
  • What are researchers hoping to learn from these trials? Researchers are aiming to determine the safety, optimal dosing, efficacy, and potential side effects of etoposide phosphate-containing regimens for different cancers. They are also studying how it interacts with other drugs.
  • Are there any unique ways etoposide phosphate is being delivered in trials? One trial is studying the use of focused ultrasound to temporarily open the blood-brain barrier to potentially improve etoposide phosphate delivery to brain tumors in children with diffuse midline gliomas.

Ongoing Clinical Trials on Etoposide Phosphate

  • Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France The Netherlands Spain Sweden

  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +4

  • Study of Larotrectinib and Drug Combination for Children with Newly Diagnosed High-Grade Glioma with NTRK Fusion

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland Iceland Latvia +6

  • Study on the Effectiveness of Etoposide Phosphate, Carboplatin, Methotrexate, Rituximab, and Cyclophosphamide in Patients with Primary Central Nervous System Lymphoma

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark Germany The Netherlands Norway Sweden

  • Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Spain

  • Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Germany Italy Slovakia

  • Study of Pembrolizumab with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

Glossary

  • Etoposide phosphate: An anticancer drug that is a water-soluble form of etoposide. It works by inhibiting DNA synthesis and causing DNA damage in cancer cells.
  • Clinical trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Chemotherapy: The use of drugs to destroy cancer cells, usually by stopping the cancer cells' ability to grow and divide.
  • Intravenous (IV): Administration of a drug or fluid directly into a vein.
  • Maximum tolerated dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Dose-limiting toxicity (DLT): Side effects of a drug or treatment that are severe enough to prevent an increase in dose or level of that treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Blood-brain barrier: A network of blood vessels and tissue that helps keep harmful substances from reaching the brain.
  • Focused ultrasound: A non-invasive therapeutic technique that uses beams of ultrasound energy to heat or disrupt tissues in the body without incisions.

References

  1. https://clinicaltrials.gov/study/NCT00002876
  2. https://clinicaltrials.gov/study/NCT06356883
  3. https://clinicaltrials.gov/study/NCT01064466
  4. https://clinicaltrials.gov/study/NCT00002880
  5. https://clinicaltrials.gov/study/NCT01900509
  6. https://clinicaltrials.gov/study/NCT05762419
  7. https://clinicaltrials.gov/study/NCT06049966